FDA Approves Expanded Indication for Ionis’ ASO Tryngolza in Severe Hypertriglyceridemia, Achieving <500 mg/dL TG Levels in 86% of Patients

July 5, 2026

Fierce Pharma USA

Overview

The FDA has approved an expanded indication for Ionis Pharmaceuticals’ antisense oligonucleotide (ASO) Tryngolza (olezarsen) for severe hypertriglyceridemia. Clinical trials demonstrated remarkable efficacy, with 86% of treated patients achieving triglyceride (TG) levels below 500 mg/dL, a threshold for acute pancreatitis risk reduction, and 54% reaching normal TG levels. This landmark approval extends Tryngolza’s utility beyond its previous rare disease indication, offering a vital new option for a broader patient population.

In Depth

Key Findings

Ionis Pharmaceuticals’ antisense oligonucleotide (ASO) therapy, Tryngolza (olezarsen), has received expanded indication approval from the U.S. FDA for the treatment of severe hypertriglyceridemia. This approval signifies a significant advancement, providing a new therapeutic option that effectively lowers triglyceride (TG) levels and reduces the risk of acute pancreatitis for a broader patient population.

Technical/Clinical Details

Tryngolza operates by targeting specific messenger RNA (mRNA) involved in the production and clearance of triglycerides, thereby suppressing the abnormal elevation of TG levels. In clinical trials for patients with severe hypertriglyceridemia, Tryngolza demonstrated a compelling efficacy profile. Specifically, 86% of treated patients achieved triglyceride levels below 500 mg/dL, a critical threshold for reducing the risk of acute pancreatitis. Furthermore, 54% of patients reached normal triglyceride levels, representing a substantial achievement for individuals whose conditions were previously difficult to manage with existing therapies. While Tryngolza was initially approved for the ultra-rare Familial Chylomicronemia Syndrome (FCS), this expanded indication allows it to benefit a much larger patient demographic.

Background & Context

Severe hypertriglyceridemia is characterized by exceptionally high levels of triglycerides in the blood, significantly increasing the risk of acute pancreatitis. Traditional treatments, including dietary modifications, exercise, and fibrates, often fail to adequately control TG levels, highlighting a high unmet medical need in this area. Ionis Pharmaceuticals is a pioneer in ASO technology, and this approval further underscores the versatility and efficacy of the ASO platform. ASOs offer a precision medicine approach by inhibiting the expression of specific genes that produce disease-causing proteins, and their development is progressing across various disease domains.

Strategic Significance & Outlook

The expanded indication for Tryngolza is expected to have a profound impact on the management of severe hypertriglyceridemia, offering a potent new option particularly for patients who have not responded sufficiently to conventional treatments or those at high risk for acute pancreatitis. This success validates the potential of ASO technology to deliver value not only in rare diseases but also in more common chronic conditions, which could accelerate the development of other ASO pipelines. As more real-world long-term efficacy and safety data become available, Tryngolza is poised to assume a crucial role in the standard of care for severe hypertriglyceridemia.

Source: https://www.fiercepharma.com/pharma/ionis-scores-landmark-fda-label-expansion-tryngolza

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.